The following NCCTG cancer treatment clinical trials are currently active. You may click on the trial number to link to a detailed description on PDQ, the National Cancer Institute's Web site for clinical trials.
| E3F05 | Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas |
| N0572 | A Phase I/II Trial of Sorafenib and CCI-779 in Patients with Recurrent Glioblastoma |
| N0574 | A Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy in Addition to Radiosurgery in the Management of Patients with One to Three Cerebral Metastases |
| N0874 | Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients with Newly Diagnosed Glioblastoma |
| N0877 | Phase I/Randomized Phase II Trial of Either Dasatinib or Placebo Combined with Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM) |
| N107C | A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease |
For more information, please discuss these trials with your physician, contact the NCCTG Operations Office or contact an NCCTG treating location near you.
Return to list of Cancer Treatment Trials
© Copyright 2012, NCCTG